Baillie Gifford & Co
RARE icon

Baillie Gifford & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

Baillie Gifford & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-115
Closed -$4.61K – 409
2023
Q1 		$4.61K Hold
115
– – ﹤0.01% 419
2022
Q4 		$5.33K Hold
115
– – ﹤0.01% 442
2022
Q3 		$5K Hold
115
– – ﹤0.01% 449
2022
Q2 		$7K Hold
115
– – ﹤0.01% 441
2022
Q1 		$8K Hold
115
– – ﹤0.01% 451
2021
Q4 		$10K Hold
115
– – ﹤0.01% 449
2021
Q3 		$10K Hold
115
– – ﹤0.01% 446
2021
Q2 		$11K Hold
115
– – ﹤0.01% 426
2021
Q1 		$13K Buy
115
+9
+8% +$1.23K ﹤0.01% 386
2020
Q4 		$15K Buy
+106
New +$12.6K ﹤0.01% 351

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baillie Gifford & Co's RARE Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2023, closing a stake of 115 shares — an estimated $4.61K sold.

Baillie Gifford & Co first reported a position in RARE in Q4 2020 and held it in 10 quarters. The position peaked at $15K in Q4 2020. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Ultragenyx Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 115 Ultragenyx Pharmaceutical shares in Q2 2023, an estimated $4.61K.
  • Baillie Gifford & Co first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Ultragenyx Pharmaceutical position peaked at $15K in Q4 2020.
  • 242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.